Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.

Research output: Contribution to journalPublished meeting abstract

Standard

Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. / Tanner, MM; Isola, JJ; Wiklund, T; Erikstein, B; Kellokumpu-Lehtinen, P; Malmström, Per; Wilking, N; Nilsson, J; Bergh, J.

In: Journal of Clinical Oncology, Vol. 23, No. 16S, 2005, p. 841S-841S.

Research output: Contribution to journalPublished meeting abstract

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.

AU - Tanner, MM

AU - Isola, JJ

AU - Wiklund, T

AU - Erikstein, B

AU - Kellokumpu-Lehtinen, P

AU - Malmström, Per

AU - Wilking, N

AU - Nilsson, J

AU - Bergh, J

PY - 2005

Y1 - 2005

M3 - Published meeting abstract

VL - 23

SP - 841S-841S

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

T2 - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

SN - 1527-7755

IS - 16S

ER -